摘要
目的观察分析瑞格列奈片联合不同胰岛素治疗老年2型糖尿病的疗效。方法筛选2017年1月—2018年1月收治的患有2型糖尿病的老年人60例为本次研究对象,按照数字随机法分成两组,所有患者采用瑞格列奈片口服,对照组患者联合门冬胰岛素30注射液皮下用药,研究组患者采用甘精胰岛素注射液皮下用药。比较两组患者治疗前后FBG、Hb A1c、2 h PG指标变化情况,并统计两组低血糖发生率、胰岛素使用剂量。结果研究组患者Hb A1c、2 h PG指标较对照组比较均不同程度下降,差异有统计学意义(P<0.05)。研究组患者胰岛素使用剂量、血糖达标时间均不同程度与对照组比较降低,两组比较差异有统计学意义(P<0.05)。结论瑞格列奈片联合甘精胰岛素注射液治疗老年糖尿病的疗效显著,且使用安全,低血糖发生率低,胰岛素使用剂量大大降低。
Objective To observe the effect of repaglinide combined with different insulin therapy on elderly patients with type 2 diabetes. Methods A total of 60 elderly patients with type 2 diabetes admitted from January 2017 and January 2018 were selected as the study subjects and divided into two groups according to the randomized method. All patients were treatedwith repaglinide orally, and patients in the control group were given insulin aspartate 30 injection subcutaneously, while patients in the study group were given insulin glargine injection subcutaneously. The changes of FBG,HbA1 c, and 2 h PG before and after treatment were compared between the two groups, and the incidence of hypoglycemia and the dose of insulin were calculated. Results The HbA1 c, 2 h PG index of the study group decreased to a certain extent compared with that of the control group, the difference was statistically significant（P 〈 0.05）. The dosage of insulin and the time to reach the standard of blood glucose in the study group were lower than those in the control group, the difference between the two groups was statistically significant（P 〈 0.05）. Conclusion Repaglinide combined with insulin glargine injection is effective for the treatment of senile diabetes,and it is safe to use. The incidence of hypoglycemia is low and the dose of insulin is greatly reduced.
作者
李积薇
LI Jiwei(Internal Medicine Department,Qixia District Maternal and Child Health Care Hospital of Nanjing,Nanjing Jiangsu 210028,China)
出处
《中国卫生标准管理》
2018年第17期82-84,共3页
China Health Standard Management
关键词
胰岛素
瑞格列奈
甘精胰岛素
预混胰岛素
口服降糖药
老年糖尿病
疗效
insulin
repaglinide
insulin glargine injection
premixed insulin
oral hypoglycemic agents
senile diabetes
efficacy
